Powered by BergacynFF®, the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials.
CHICAGO, IL / ACCESS Newswire / April 8, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the planned Q2 2026 U.S. launch of Liv18™, a next-generation liver health supplement powered by BergacynFF®, the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials.
The Liver Fat Epidemic: $7+ Billion Projected U.S. Market Opportunity
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as one of the most prevalent and underdiagnosed conditions in the United States. More than 30% of adults are estimated to be affected, with the condition closely linked to obesity, type 2 diabetes, and metabolic syndrome. While recent therapeutic advancements have emerged for certain patient populations, significant unmet need remains for safe, accessible, and preventive solutions supporting liver and metabolic health.
>30% of U.S. adults affected by NAFLD/MASLD | $4.6B U.S. liver health supplements market | 4.9% CAGR projected growth through 2035 |
Sources: Precedence Research
The Science Behind Liv18™: BergacynFF®
Liv18™ is built on BergacynFF®, a patented extract blend of Citrus bergamia (Italian bergamot) and Cynara cardunculus sylvestris (wild Italian artichoke thistle leaf). The ingredient delivers a proprietary profile of bergamot polyphenols (17% flavonone content), bergamot pulp fibers, and artichoke sesquiterpenes (5% cynaropicrin), whose synergistic action has been validated in two independent randomized, double-blind, placebo-controlled clinical trials.
Clinical Evidence Summary:
Study | Population | Key Findings | Publication |
Study 1 - 16 weeks | 80 subjects, NAFLD + Type 2 Diabetes | ALT ↓15 pts, AST ↓18 pts (p |